Inhibition of PCSK9 in familial hypercholesterolaemia

被引：5
|
作者：
Sijbrands, Eric J. G. [1 ,2 ]
机构：
[1] Erasmus MC, Pharmacol Vasc & Metab Dis sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol & Internal Med, Cardiovasc Genet Sect, NL-3000 CA Rotterdam, Netherlands
来源：
LANCET | 2012年 / 380卷 / 9836期
关键词：
APOLIPOPROTEIN-B; CONTROLLED-TRIAL; LDL CHOLESTEROL; DOUBLE-BLIND; STATIN; ATHEROSCLEROSIS; MIPOMERSEN; EZETIMIBE; EFFICACY; THERAPY;
D O I：
10.1016/S0140-6736(12)60814-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [1] Familial hypercholesterolaemia: PCSK9 inhibitors are coming
    Santos, Raul D.
    Watts, Gerald F.
    LANCET, 2015, 385 (9965) : 307 - 310
  • [2] PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?
    Paquette, Martine
    Hegele, Robert A.
    Baass, Alexis
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1106 - 1108
  • [3] PCSK9 inhibition in the management of familial hypercholesterolemia
    Ogura, Masatsune
    JOURNAL OF CARDIOLOGY, 2018, 71 (1-2) : 1 - 7
  • [4] Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
    Wierzbicki, Anthony S.
    Grant, Paul
    CLINICAL MEDICINE, 2016, 16 (04) : 353 - 357
  • [5] Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
    Pecin, Ivan
    Hartgers, Merel L.
    Hovingh, G. Kees
    Dent, Ricardo
    Reiner, Zeljko
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (13) : 1383 - 1401
  • [6] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [7] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [8] The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation
    Noguchi, Tohru
    Katsuda, Shoji
    Kawashiri, Masa-aki
    Tada, Hayato
    Nohara, Atsushi
    Inazu, Akihiro
    Yamagishi, Masakazu
    Kobayashi, Junji
    Mabuchi, Hiroshi
    ATHEROSCLEROSIS, 2010, 210 (01) : 166 - 172
  • [9] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [10] The consequences of PCSK9 inhibition in selected tissues
    Maliglowka, Mateusz
    Buldak, Lukasz
    Okopien, Boguslaw
    Boldys, Aleksandra
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2021, 75 : 385 - 397
12345